Table 4– Numbers of patients reporting at least one asthma-related nonfatal serious adverse event by age, sex and race in the primary dataset
Formoterol-containing productsNon-LABA-containing products
Age group years
 4–1139/3264 (1.2)25/2165 (1.2)
 12–1724/5088 (0.5)17/1989 (0.9)
 18–64335/52 492 (0.6)141/13 911 (1.1)
 >6565/6494 (1.0)21/1467 (1.4)
 Unknown0/42 (0.0)0/0 (0.0)
Sex
 Male174/28 627 (0.7)72/8264 (0.9)
 Female289/38 577 (0.8)132/10 353 (1.3)
 Unknown0/176 (0.0)0/123 (0.0)
Race
 Caucasian288/44 581 (0.6)123/14 931 (0.8)
 Black11/1434 (0.8)8/847 (0.9)
 Oriental103/5398 (1.9)53/1916 (2.8)
 Other25/2335 (1.1)20/1046 (1.9)
 Unknown36/16 362 (0.3)0/0 (0.0)
Total463/67 380 (0.7)204/18 740 (1.1)

  • Data are presented as n/N (%). LABA: long-acting β-agonist.